Japan PHarmacological Audit study of Safety and Efficacy in Real world (Phase-R) ESAS Study

Japan PHarmacological Audit study of Safety and Efficacy in Real world (Phase-R) ESAS Study - Phase-R ESAS Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025269

Enrollment

400

Registered

2016-12-14

Start date

2016-09-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignancy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: adult patients with cancer who admit to inpatient palliative care units.

Exclusion criteria

Exclusion criteria: Patients who cannot answer ESAS scoring due to consciousness disturbance or severe deterioration.

Design outcomes

Primary

Measure	Time frame
Edmonton Symptom Assessment System (ESAS) scores on admission, day 3, and day 7	—

Secondary

Measure	Time frame
patients' characteristics, co-morbidity, performance status, symptoms, prognostication, laboratory data, concomitant treatments	—

Countries

Japan

Contacts

Public ContactKeisuke Ariyoshi

The University of Tokyo, The Institute of Medical Science Department of Palliative Medicine

k-ariyoshi@umin.ac.jp03-3443-7111

Outcome results